313 related articles for article (PubMed ID: 18005117)
1. The use of topical calcineurin inhibitors in lupus erythematosus: an overview.
Wollina U; Hansel G
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):1-6. PubMed ID: 18005117
[TBL] [Abstract][Full Text] [Related]
2. Potential new indications of topical calcineurin inhibitors.
Luger T; Paul C
Dermatology; 2007; 215 Suppl 1():45-54. PubMed ID: 18174692
[TBL] [Abstract][Full Text] [Related]
3. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative.
Lampropoulos CE; Sangle S; Harrison P; Hughes GR; D'Cruz DP
Rheumatology (Oxford); 2004 Nov; 43(11):1383-5. PubMed ID: 15266063
[TBL] [Abstract][Full Text] [Related]
4. Pimecrolimus 1% cream for cutaneous lupus erythematosus.
Kreuter A; Gambichler T; Breuckmann F; Pawlak FM; Stücker M; Bader A; Altmeyer P; Freitag M
J Am Acad Dermatol; 2004 Sep; 51(3):407-10. PubMed ID: 15337984
[TBL] [Abstract][Full Text] [Related]
5. Association between exposure to topical tacrolimus or pimecrolimus and cancers.
Hui RL; Lide W; Chan J; Schottinger J; Yoshinaga M; Millares M
Ann Pharmacother; 2009 Dec; 43(12):1956-63. PubMed ID: 19903860
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous lupus erythematosus: issues in diagnosis and treatment.
Walling HW; Sontheimer RD
Am J Clin Dermatol; 2009; 10(6):365-81. PubMed ID: 19824738
[TBL] [Abstract][Full Text] [Related]
7. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.
Schneeweiss S; Doherty M; Zhu S; Funch D; Schlienger RG; Fernandez-Vidaurre C; Seeger JD
Dermatology; 2009; 219(1):7-21. PubMed ID: 19293564
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus.
Sugano M; Shintani Y; Kobayashi K; Sakakibara N; Isomura I; Morita A
J Dermatol; 2006 Dec; 33(12):887-91. PubMed ID: 17169097
[TBL] [Abstract][Full Text] [Related]
9. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis.
Yoshimasu T; Ohtani T; Sakamoto T; Oshima A; Furukawa F
Eur J Dermatol; 2002; 12(1):50-2. PubMed ID: 11809595
[TBL] [Abstract][Full Text] [Related]
10. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation.
Tzellos TG; Kouvelas D
Eur J Clin Pharmacol; 2008 Apr; 64(4):337-41. PubMed ID: 18157526
[TBL] [Abstract][Full Text] [Related]
11. Pimecrolimus and tacrolimus: the US FDA public health advisory.
Maddin S
Skin Therapy Lett; 2005 May; 10(4):1-3. PubMed ID: 15986080
[No Abstract] [Full Text] [Related]
12. Topical calcineurin inhibitors for the treatment of vulvar dermatoses.
Goldstein AT; Thaçi D; Luger T
Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):22-9. PubMed ID: 19631446
[TBL] [Abstract][Full Text] [Related]
13. Topical pimecrolimus in the treatment of seborrheic dermatitis.
Brownell I; Quan LT; Hsu S
Dermatol Online J; 2003 Aug; 9(3):13. PubMed ID: 12952760
[TBL] [Abstract][Full Text] [Related]
14. [New immune suppressants: topical immunomodulatory agents].
Senatorski G; Sułowicz W; Paczek L
Przegl Lek; 2002; 59(11):907-11. PubMed ID: 12715720
[TBL] [Abstract][Full Text] [Related]
15. Topical pimecrolimus 1% for the treatment of pruritic external auditory canals.
Djalilian HR; Memar O
Laryngoscope; 2006 Oct; 116(10):1809-12. PubMed ID: 17003726
[TBL] [Abstract][Full Text] [Related]
16. Topical pimecrolimus in the treatment of vitiligo.
Boone B; Ongenae K; Van Geel N; Vernijns S; De Keyser S; Naeyaert JM
Eur J Dermatol; 2007; 17(1):55-61. PubMed ID: 17324829
[TBL] [Abstract][Full Text] [Related]
17. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.
Thaçi D; Salgo R
Clin Dermatol; 2010; 28(1):52-6. PubMed ID: 20082951
[TBL] [Abstract][Full Text] [Related]
18. [Topical pimecrolimus and tacrolimus and the risk of cancer].
Sánchez-Pérez J
Actas Dermosifiliogr; 2007 Jun; 98(5):312-7. PubMed ID: 17555673
[TBL] [Abstract][Full Text] [Related]
19. Topical tacrolimus and pimecrolimus in the treatment of oral lichen planus: an update.
López-Jornet P; Camacho-Alonso F; Salazar-Sanchez N
J Oral Pathol Med; 2010 Mar; 39(3):201-5. PubMed ID: 19943858
[TBL] [Abstract][Full Text] [Related]
20. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.
Berger TG; Duvic M; Van Voorhees AS; VanBeek MJ; Frieden IJ;
J Am Acad Dermatol; 2006 May; 54(5):818-23. PubMed ID: 16635663
[No Abstract] [Full Text] [Related]
[Next] [New Search]
